share_log

藥明合聯：正面盈利預告及業務最新消息

WUXI XDC: POSITIVE PROFIT ALERT AND BUSINESS UPDATE

香港交易所 ·  Feb 1 06:07
Summary by Futu AI
药明合联生物技術有限公司預告2023年度未經審核綜合管理賬目顯示，公司銷售收入及淨利潤均實現顯著增長。根據初步評估，銷售收入增長超過100%，淨利潤增長超過80%，經調整淨利潤增長超過100%。這一增長主要得益於抗體藥物偶聯物（ADC）行業的活躍發展及公司在該領域的競爭優勢。公司於2023年11月上市後，成功獲得多個生產工藝驗證項目（PPQ）並與多家專注於ADC開發的生物科技公司簽署技術合作項目。董事會對未來業務前景表示充滿信心。股東及潛在投資者應留意，這些數據尚未經過審核，且有待最終定稿及可能的其他調整。公司將於2024年3月底公布截至2023年12月31日止年度的全年業績公告。
药明合联生物技術有限公司預告2023年度未經審核綜合管理賬目顯示，公司銷售收入及淨利潤均實現顯著增長。根據初步評估，銷售收入增長超過100%，淨利潤增長超過80%，經調整淨利潤增長超過100%。這一增長主要得益於抗體藥物偶聯物（ADC）行業的活躍發展及公司在該領域的競爭優勢。公司於2023年11月上市後，成功獲得多個生產工藝驗證項目（PPQ）並與多家專注於ADC開發的生物科技公司簽署技術合作項目。董事會對未來業務前景表示充滿信心。股東及潛在投資者應留意，這些數據尚未經過審核，且有待最終定稿及可能的其他調整。公司將於2024年3月底公布截至2023年12月31日止年度的全年業績公告。
Pharmaceutical United Biotechnology Co., Ltd. announces that the company's unaudited consolidated management accounts for 2023 showed significant growth in sales revenue and net profit. According to preliminary estimates, sales revenue grew by more than 100%, net profit grew by more than 80%, and adjusted net profit grew by more than 100%. This growth is mainly due to the active development of the Antibody Drug Duplicate (ADC) industry and the company's competitive advantage in this field. After going public in November 2023, the company successfully obtained several production process verification projects (PPQs) and signed technical cooperation projects with several biotech companies focused on ADC development. The Board of Directors expressed confidence in the future business outlook. Shareholders and potential investors should note that these data have not yet been audited and are subject to final draft and possible other adjustments. THE COMPANY WILL ANNOUNCE THE ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023 AT THE END OF MARCH 2024.
Pharmaceutical United Biotechnology Co., Ltd. announces that the company's unaudited consolidated management accounts for 2023 showed significant growth in sales revenue and net profit. According to preliminary estimates, sales revenue grew by more than 100%, net profit grew by more than 80%, and adjusted net profit grew by more than 100%. This growth is mainly due to the active development of the Antibody Drug Duplicate (ADC) industry and the company's competitive advantage in this field. After going public in November 2023, the company successfully obtained several production process verification projects (PPQs) and signed technical cooperation projects with several biotech companies focused on ADC development. The Board of Directors expressed confidence in the future business outlook. Shareholders and potential investors should note that these data have not yet been audited and are subject to final draft and possible other adjustments. THE COMPANY WILL ANNOUNCE THE ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023 AT THE END OF MARCH 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.